Targeted axillary dissection (TAD) is a relatively new breast cancer procedure. It allows surgical oncologists to specifically locate a lymph node that contained cancer before chemotherapy, remove it ...

Neoadjuvant dose-dense anthracycline and cyclophosphamide in combination with carboplatin, paclitaxel, and pembrolizumab for triple-negative breast cancer: A systematic review and meta-analysis. This ...

Skipping standard axillary lymph node dissection led to very low rates of axillary recurrence in patients with node-positive breast cancer who became node-negative following neoadjuvant chemotherapy, ...

Patients with clinically node-negative breast cancer after neoadjuvant chemotherapy demonstrated low axillary and locoregional recurrence rates after sentinel lymph node biopsy (SLNB) or targeted ...

This Canadian study included 111 women (median age 63 years), most of whom (90%, n=100) had invasive ductal carcinoma. Over the entire cohort, more than half (54%, n=60) underwent mastectomy and 46% ...

Future breast cancer treatment options may not only increase patients’ survival but also reduce or eliminate their need for surgery altogether, says breast cancer surgeon Sara Javid, MD, Fred ...

MIAMI BEACH -- The surgical dogma favoring axillary dissection in breast cancer continues to give way to more selective data-driven strategies that allow more women to avoid axillary surgery, an ...

Please provide your email address to receive an email when new articles are posted on . Patients with pathologic complete response after neoadjuvant systemic therapy remained disease-free at 5 years ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Omission of completion axillary lymph node dissection did not increase recurrence among patients ...